Baby tamoxifen shows promise in preventing breast cancer recurrence

NCT ID NCT06982313

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study follows up on women who took a low dose of tamoxifen (5 mg daily) for three years to see if it continues to prevent breast cancer over the long term. The original trial found a 42% reduction in breast cancer events. Researchers will also combine data from three similar studies to get stronger evidence. The goal is to confirm that low-dose tamoxifen is a safe and effective prevention option for women with high-risk breast lesions.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
tamoxifen (low-dose, 5 mg daily)
What this could lead to
If successful, this could confirm that a low dose of tamoxifen is a safe and effective way to prevent breast cancer in women with high-risk breast changes.
What could go wrong
This is a follow-up study, not a new treatment test. The results may not apply to all women, and long-term side effects are still being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL DUCTAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Study site

    Genova, Italy, 16145, Italy

  • E. O. Ospedali Galliera

    Genoa, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.